Why Johnson & Johnson (JNJ) Is One of the Best Pharma Stocks to Invest in Now

Johnson & Johnson (NYSE:JNJ) is one of the best pharma stocks to invest in now. Johnson & Johnson (NYSE:JNJ) announced on March 28 that randomized controlled trial (RCT) data presented at the American College of Cardiology (ACC) 2026, which was also published in the Journal of the American College of Cardiology, showed for the first time that supporting the left ventricle with an Impella CP for more than 40 minutes prior to reperfusion neither increases nor reduces heart muscle damage, which is known as a myocardial infarction. The company further stated that findings from the trial support future studies on whether pre-PCI treatment with Impella CP opens a window of time that enables delivery of adjunct pharmacotherapies designed to reduce reperfusion injury. It also cited the correlation of greater infarct size and an increased risk of death or the development of heart failure.

CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says

Johnson & Johnson (NYSE:JNJ) added that the STEMI DTU (ST-segment Elevation Myocardial Infarction Door-To-Unloading) RCT2, as a mechanistic study, investigates the impact of LV unloading on infarct size, with the overall findings being neutral because the trial’s primary endpoint did not demonstrate that LV support plus delayed reperfusion reduces heart muscle damage in patients with anterior STEMI without cardiogenic shock compared with PCI alone.

Johnson & Johnson (NYSE:JNJ) develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, including oncology, infectious diseases, immunology, cardiovascular and metabolic diseases, and others. The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.